Which factors shape and limit the role of the center for drug evaluation and research's advisory committees?

Drug Information Journal

Volumn 36, Issue 2, 2002, Pages 281-289

  Schulman, Sara ^a   Olson, Mary K ^a   Makuch, Robert W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Advisory committees; Conflicts of interest; FDA

Indexed keywords

CONFERENCE PAPER; DRUG APPROVAL; DRUG LEGISLATION; DRUG RESEARCH; DRUG SCREENING; ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; ORGANIZATION; PRIORITY JOURNAL; UNITED STATES;

EID: 0036374981     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150203600206     Document Type: Conference Paper

References (15)

1. Cauchon D. FDA advisors tied to industry: Drug-approval process riddled with conflicts of interest, analysis finds. USA Today Sept. 25, 2000: 1A.
2. Conflicts of interest in U.S. advisory panels. Scrip Daily News. Aug. 30, 2000: 2570/71.
3. FDA meetings should exclude members with conflicts of interest. Pink Sheet. June 26, 2000: 9.
4. House investigates panels involved with drug safety. Washington Times. June 18, 2001:Al.
5. Food and Drug Administration. Policy and Guidance Handbook for FDA Advisory Committees. Washington DC: Food and Drug Administration; 1994.
6. Institute of Medicine. Food and Drug Administration Advisory Committees. Rettig ER, Earley LE, Merrill RA, eds. Washington, DC: National Academy Press; 1992.
7. Federal Advisory Committee Act, s3(1), 1972.
8. Smith BLR. The Advisors: Scientists in the Policy Process. Washington DC: Brookings Institution; 1992.
9. 21 CFR 14.171, 1993.
10. Guidance for industry on advisory committees: Implementing Section 120 of the Food and Drug Administration Modernization Act. Federal Register Nov. 2, 1998: 58746.
11. United States Department of Health and Human Services. FDA Public Advisory Groups: Authority, Structure, Function, Members. Washington, DC: Department of Health and Human Services; 1999.
12. Disclosing Information Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by the Center for Drug Evaluation and Research, Beginning on January 1, 2000. Draft guidance. http://www.fda.gov/cder/guidance/3479dft.htm.
13. Food and Drug Administration. Waiver Criteria Document 2000. Washington DC: Food and Drug Administration; 2000.
14. Food and Drug Administration. FDA Advisory Committees, http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.
15. Interpretation, exemptions and waiver guidance conceming 18 U.S.C. 208. Federal Register. Sept. 11, 1995: 47220.